Results 1 to 10 of about 8,701 (200)
Ergotamine Targets KIF5A to Facilitate Anoikis in Lung Adenocarcinoma. [PDF]
Clin Respir JKinesin family member 5A (KIF5A) inhibits lung adenocarcinoma (LUAD) cell anoikis, while the small molecule drug Ergotamine targets and inhibits the expression of KIF5A, which in turn induces LUAD cell anoikis. ABSTRACT Background Kinesin family member 5A (KIF5A) has been reported to be closely related to cancer progression.
Bao B, Yu X, Zheng W, Sun J.
europepmc +3 more sources
Do antithrombotic drugs have a role in migraine prevention? A systematic review. [PDF]
HeadacheAbstract Objectives To explore the available evidence on the role of antithrombotics as migraine preventive medication. Background In clinical practice, the use of antithrombotic drugs in individuals with migraine is sometimes considered, especially in the case of frequent auras, association with patent foramen ovale, or prothrombotic states.
De Santis F +7 more
europepmc +2 more sources
Rates and risk factors for migraine progression using multiple definitions of progression: Results of the longitudinal OVERCOME (US) study. [PDF]
HeadacheAbstract Objective To estimate rates of migraine progression and assess predictors of progression in a large, longitudinal cohort study using the traditional definition and two alternative definitions of migraine progression. Background Traditionally, migraine progression is defined as moving from episodic migraine (EM) with ≤ 14 monthly headache days (
Buse DC +8 more
europepmc +2 more sources
Pain PractABSTRACT Introduction Cluster headache is a rare primary headache disorder characterized by excruciating unilateral pain around the eye, lasting between 15 and 180 min, accompanied by ipsilateral cranial autonomic symptoms. Cluster headache is classified into two forms: episodic and chronic, with chronic cluster headache defined by pain‐free intervals ...
Lansbergen CS +5 more
europepmc +2 more sources
ChemMedChem, Accepted Article.We have described the synthesis of a new series of LCAPs (long‐chain arylpiperazine) as serotoninergic ligands (FG 1‐18). The combination of structural elements including heterocyclic nucleus, propyl chain and 4,5‐dihydrothiazol‐2‐ylphenylpiperazines, led to the preparation of different derivatives tested for their affinity toward 5‐HT1A, 5‐HT2A and 5 ...
Giorgia Andreozzi +18 more
wiley +1 more source
British Journal of Pharmacology, EarlyView.Abstract G protein‐coupled receptors (GPCRs) are one of the major drug targets. In recent years, computational drug design for GPCRs has mainly focused on static structures obtained through X‐ray crystallography, cryogenic electron microscopy (cryo‐EM) or in silico modelling as a starting point for virtual screening campaigns. However, GPCRs are highly
Marta Lopez‐Balastegui +6 more
wiley +1 more source
Progress on the development of Class A GPCR‐biased ligands
British Journal of Pharmacology, EarlyView.Class A G protein‐coupled receptors (GPCRs) continue to garner interest for their essential roles in cell signalling and their importance as drug targets. Although numerous drugs in the clinic target these receptors, over 60% GPCRs remain unexploited. Moreover, the adverse effects triggered by the available unbiased GPCR modulators, limit their use and
Paula Morales +20 more
wiley +1 more source
Preclinical models for evaluating psychedelics in the treatment of major depressive disorder
British Journal of Pharmacology, EarlyView.Psychedelic drugs have seen a resurgence in interest as a next generation of psychiatric medicines with potential as rapid‐acting antidepressants (RAADs). Despite promising early clinical trials, the mechanisms which underlie the effects of psychedelics are poorly understood.
Laith Alexander +5 more
wiley +1 more source
Neuropsychopharmacology of hallucinogenic and non‐hallucinogenic 5‐HT2A receptor agonists
British Journal of Pharmacology, EarlyView.Psychedelic drugs such as LSD and psilocin were once relegated to the fringes of medical research because of their association with counterculture movements and a perceived concern about harm through recreational use, and their consequent legal prohibition in the early 1970s.
Trevor Sharp, Aurelija Ippolito
wiley +1 more source
Headache: The Journal of Head and Face Pain, Volume 65, Issue 6, Page 919-932, June 2025.Abstract Objective To estimate the real‐world risk of cardiovascular events among patients with migraine treated with erenumab and other migraine preventive medications. Background Migraine preventive treatment with calcitonin gene‐related peptide (CGRP) pathway inhibitors, such as erenumab and others, may theoretically result in cardiovascular effects
David W. Dodick +9 more
wiley +1 more source